Immunologically active phenotype by gene expression profiling is associated with clinical benefit from PD-1/PD-L1 inhibitors in real-world head and neck and lung cancer patients.
Foy JP, Karabajakian A, Ortiz-Cuaran S, Boussageon M, Michon L, Bouaoud J, Fekiri D, Robert M, Baffert KA, Hervé G, Quilhot P, Attignon V, Girod A, Chaine A, Benassarou M, Zrounba P, Caux C, Ghiringhelli F, Lantuejoul S, Crozes C, Brochériou I, Pérol M, Fayette J, Bertolus C, Saintigny P.
Foy JP, et al. Among authors: chaine a.
Eur J Cancer. 2022 Oct;174:287-298. doi: 10.1016/j.ejca.2022.06.034. Epub 2022 Aug 26.
Eur J Cancer. 2022.
PMID: 36038492